A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of application
A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.
대표청구항▼
1. A composition for oral administration to a subject, comprising: a. magnesium threonate; andb. at least one component of non-acidified milk sufficient to enhance bioavailability of elemental magnesium of the magnesium threonate,wherein a mass ratio of the amount of elemental magnesium of the magne
1. A composition for oral administration to a subject, comprising: a. magnesium threonate; andb. at least one component of non-acidified milk sufficient to enhance bioavailability of elemental magnesium of the magnesium threonate,wherein a mass ratio of the amount of elemental magnesium of the magnesium threonate and the amount of the at least one component of said non-acidified milk is from about 1 to about 5 to about 1 to about 3000. 2. The composition of claim 1, further comprising at least one magnesium comprising component (MCC) selected from magnesium citrate, magnesium gluconate, magnesium lactate, and magnesium malate. 3. The composition of claim 2, further comprising from about 5 to about 50 percent magnesium citrate, from about 10 to about 70 percent magnesium gluconate, and from about 5 to about 50 percent magnesium lactate, wherein each percent is a weight percent relative to the total weight of the magnesium citrate, magnesium lactate and magnesium gluconate. 4. The composition of claim 1, wherein the at least one component of said non-acidified milk comprises milk fat. 5. The composition of claim 1, wherein the at least one component of said non-acidified milk comprises lactose. 6. The composition of claim 1, wherein the at least one component of said non-acidified milk has a pH of from about 5.7 to about 7.2. 7. The composition of claim 1, wherein the magnesium threonate is present in at least an amount effective for maintenance of cognitive function. 8. The composition of claim 1, wherein the magnesium threonate is present in at least an amount effective for enhancement of cognitive function. 9. The composition of claim 1, wherein the magnesium threonate is present in at least an amount effective for treatment of Alzheimer's disease. 10. The composition of claim 1, wherein the composition is in a form selected from liquid, gel, semi-liquid, semi-solid, and solid. 11. The composition of claim 1, wherein the composition is in a liquid form. 12. The composition of claim 11, wherein the concentration of elemental magnesium associated with the magnesium threonate is from about 5 mg/L to about 12 g/L. 13. The composition of claim 1, wherein the composition is sufficient to provide from about 1.5 mg/kg of body weight/day to about 18 mg/kg of body weight/day of elemental magnesium associated with the magnesium threonate. 14. An oral dosage form comprising magnesium threonate, wherein the oral dosage form comprises 300 mg to 1.5 g elemental magnesium. 15. The oral dosage form of claim 14, wherein said oral dosage form is a tablet. 16. The oral dosage form of claim 14, wherein said oral dosage form is a capsule. 17. The oral dosage form of claim 14, wherein said oral dosage form is a liquid. 18. The oral dosage form of claim 14, wherein said oral dosage form comprises a plurality of beads encapsulated in a capsule. 19. An oral dosage comprising a pharmaceutically active agent and an excipient, wherein the excipient is magnesium threonate, and wherein the oral dosage is solid or semi-solid. 20. A composition for oral administration to a subject, comprising: magnesium threonate in an amount effective for maintenance and/or enhancement of cognitive function, wherein said composition is in a formulation suitable for oral administration to a subject. 21. The composition of claim 20, wherein magnesium threonate is present in at least an amount effective for treatment of Alzheimer's disease. 22. The composition of claim 20, further comprising at least one component of non-acidified milk sufficient to enhance bioavailability of elemental magnesium associated with magnesium threonate. 23. The composition of claim 22, wherein the at least one component comprises milk fat. 24. The composition of claim 22, wherein the at least one component comprises lactose. 25. The composition of claim 20, wherein the composition is in a form selected from liquid, gel, semi-liquid, semi-solid, and solid. 26. The composition of claim 20, wherein the composition is in a liquid form. 27. The composition of claim 20, wherein the concentration of elemental magnesium in magnesium threonate is from about 5 mg/L to about 12 g/L. 28. The composition of claim 20, wherein the composition is sufficient to provide from about 1.5 mg/kg of body weight/day to about 18 mg/kg of body weight/day of elemental magnesium. 29. A method of providing magnesium supplementation to a subject, comprising: orally administering to the subject the composition of claim 1.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (11)
William T. Evans ; Dwight L. McKee, Alkali or alkaline earth metal of n-butyric acid for treatment of cognitive and emotional conditions.
George H. Clark ; Mary Ann Clark, Carbonated fortified milk-based beverage and method of making carbonated fortified milk-based beverage for the supplementation of essential nutrients in the human diet.
Yu Kai,CNX ; Wang Zhiwen,CNX ; Kou Fuping,CNX, L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof.
Skyler Jay S. (Key Biscayne FL) Frost Phillip (Miami Beach FL) Hahn Elliot F. (North Miami Beach FL), Method and composition for treatment of insulin resistance syndromes.
Glick J. Leslie (Potomac MD), Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory lo.
Atalla Rajai H. (Verona WI) Weinstock Ira A. (Madison WI) Hill Craig L. (Atlanta GA) Reiner Richard S. (Madison WI), Oxidation of lignin and polysaccharides mediated by polyoxometalate treatment of wood pulp.
Costa Jonathan L. (Wheaton IL) Diazgranados Jesus A. (Cali COX), Treatment of human diseases involving dysregulation or dysfunction of the nervous system.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.